《大行報告》美銀證券上調匯控(00005.HK)目標價至39.66元 降未來信貸撥備預測
美銀證券發表報告指,藥廠輝瑞公布研發中的新型肺炎疫苗有效性高,降低了2022年經濟疲弱的風險,因此下調對匯控(00005.HK)2022年的信貸撥備預測8%至39.53億美元,維持對其2021年除稅前盈利120.76億美元預測,並上調對其2022年除稅前盈利預測4%至156.68億美元。
該行表示,美元匯率有上升跡象,市場現時認為美匯三年之內將上升但幅度不大,雖然匯控所持直接的長債非常有限,但隨著全球利率環境改善,及其經常賬有1萬億美元,顯示低收益率可能是周期性而非永久性。
美銀證券表示,上調匯控股份目標價,由35.42元升至39.66元,維持「中性」評級。該行料匯控於2020年至2022年純利預測各為27.6億美元、58.6億美元及94.96億美元,料2020年至2022年每股盈利預測各為0.13美元、0.28美元及0.46美元,料匯控2020年至2022年每股派息預測各各為0.12美元、0.16美元及0.2美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.